Alendronic acid | CAS#66376-36-1 | nonhormonal medication

MedKoo Cat#: 592514 | Name: Alendronic acid

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Alendronic acid is a nonhormonal medication for the treatment of postmenopausal osteoporosis in women. This drug builds healthy bone, restoring some of the bone loss as a result of osteoporosis.

Chemical Structure

Alendronic acid

CAS#66376-36-1 (free acid)

Theoretical Analysis

MedKoo Cat#: 592514

Name: Alendronic acid

CAS#: 66376-36-1 (free acid)

Chemical Formula: C4H13NO7P2

Exact Mass: 249.0167

Molecular Weight: 249.10

Elemental Analysis: C, 19.29; H, 5.26; N, 5.62; O, 44.96; P, 24.87

Price and Availability

Size	Price	Availability	Quantity
1g	USD 250.00	2 Weeks
5g	USD 450.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

121268-17-5 (sodium) 66376-36-1 (free acid) 137504-90-6 (calcium) 138624-11-0 (free acid hydrate)

Synonym

Alendronic acid; MK 217; MK-217; MK217; Alendronate; Arendal;

IUPAC/Chemical Name

(4-Amino-1-hydroxybutylidene)diphosphonic acid

InChi Key

OGSPWJRAVKPPFI-UHFFFAOYSA-N

InChi Code

InChI=1S/C4H13NO7P2/c5-3-1-2-4(6,13(7,8)9)14(10,11)12/h6H,1-3,5H2,(H2,7,8,9)(H2,10,11,12)

SMILES Code

OC(P(O)(O)=O)(P(O)(O)=O)CCCN

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined.

Shelf Life

>3 years if stored properly

Drug Formulation

To be determined.

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Certificate of Analysis

View CoA: current batch, Lot#T21C09I22

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 249.10 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Available from http://www.ncbi.nlm.nih.gov/books/NBK501621/ PubMed PMID: 30000682. 2: Martín-Merino E, Calderón-Larrañaga A, Hawley S, Poblador-Plou B, Llorente-García A, Petersen I, Prieto-Alhambra D. The impact of different strategies to handle missing data on both precision and bias in a drug safety study: a multidatabase multinational population-based cohort study. Clin Epidemiol. 2018 Jun 5;10:643-654. doi: 10.2147/CLEP.S154914. eCollection 2018. PubMed PMID: 29892204; PubMed Central PMCID: PMC5993167. 3: Nsubuga A, Sgarzi M, Zarschler K, Kubeil M, Hübner R, Steudtner R, Graham B, Joshi T, Stephan H. Facile preparation of multifunctionalisable 'stealth' upconverting nanoparticles for biomedical applications. Dalton Trans. 2018 Jul 14;47(26):8595-8604. doi: 10.1039/c8dt00241j. Epub 2018 Apr 25. PubMed PMID: 29691531. 4: Young RN, Grynpas MD. Targeting therapeutics to bone by conjugation with bisphosphonates. Curr Opin Pharmacol. 2018 Jun;40:87-94. doi: 10.1016/j.coph.2018.03.010. Epub 2018 Apr 4. Review. PubMed PMID: 29626715. 5: McCadden L, Leonard CG, Primrose WJ. Bisphosphonate-induced osteonecrosis of the ear canal: our experience and a review of the literature. J Laryngol Otol. 2018 Apr;132(4):372-374. doi: 10.1017/S0022215118000324. Epub 2018 Feb 28. Review. PubMed PMID: 29486808. 6: Yoon BH, Park SB. Insufficiency Fracture Occurring 3 Years After Union of an Intertrochanteric Hip Fracture: A Case Report. JBJS Case Connect. 2017 Jan-Mar;7(1):e1. doi: 10.2106/JBJS.CC.16.00006. PubMed PMID: 29244683. 7: Nguyen TDT, Pitchaimani A, Ferrel C, Thakkar R, Aryal S. Nano-confinement-driven enhanced magnetic relaxivity of SPIONs for targeted tumor bioimaging. Nanoscale. 2017 Dec 21;10(1):284-294. doi: 10.1039/c7nr07035g. PubMed PMID: 29210434. 8: Zhang Y, Chen X, Tang Y, Lu Y, Guo L, Zhong D. Bioequivalence of generic alendronate sodium tablets (70 mg) to Fosamax(®) tablets (70 mg) in fasting, healthy volunteers: a randomized, open-label, three-way, reference-replicated crossover study. Drug Des Devel Ther. 2017 Jul 11;11:2109-2119. doi: 10.2147/DDDT.S138286. eCollection 2017. PubMed PMID: 28744102; PubMed Central PMCID: PMC5513855. 9: Xie H, Chen G, Young RN. Design, Synthesis, and Pharmacokinetics of a Bone-Targeting Dual-Action Prodrug for the Treatment of Osteoporosis. J Med Chem. 2017 Aug 24;60(16):7012-7028. doi: 10.1021/acs.jmedchem.6b00951. Epub 2017 Aug 10. PubMed PMID: 28699744. 10: Hodgins NO, Wang JT, Al-Jamal KT. Nano-technology based carriers for nitrogen-containing bisphosphonates delivery as sensitisers of γδ T cells for anticancer immunotherapy. Adv Drug Deliv Rev. 2017 May 15;114:143-160. doi: 10.1016/j.addr.2017.07.003. Epub 2017 Jul 8. Review. PubMed PMID: 28694026. 11: Phillips HK, Harrison SJ, Akrawi H, Sidhom SA. Retrospective review of patients with atypical bisphosphonate related proximal femoral fractures. Injury. 2017 Jun;48(6):1159-1164. doi: 10.1016/j.injury.2017.03.025. Epub 2017 Apr 4. PubMed PMID: 28410753. 12: Symington M, Davies L, Kaltsas G, Weickert MO. Malignant hypercalcaemia related to parathyroid hormone-related peptide (PTHrP) secretion from a metastatic pancreatic neuroendocrine tumour (NET). BMJ Case Rep. 2017 Mar 22;2017. pii: bcr2017219692. doi: 10.1136/bcr-2017-219692. PubMed PMID: 28331027. 13: Marongiu G, Capone A. Atypical periprosthetic acetabular fracture in long-term alendronate therapy. Clin Cases Miner Bone Metab. 2016 Sep-Dec;13(3):209-213. doi: 10.11138/ccmbm/2016.13.3.209. Epub 2017 Feb 10. PubMed PMID: 28228784; PubMed Central PMCID: PMC5318174. 14: Couture G, Delzor F, Bagheri H, Micallef J, Ruyssen-Witrand A, Laroche M. First cases of calcium pyrophosphate deposition disease after zoledronic acid therapy. Joint Bone Spine. 2017 Mar;84(2):213-215. doi: 10.1016/j.jbspin.2016.11.004. Epub 2016 Dec 6. PubMed PMID: 27939801. 15: Ke J, Dou H, Zhang X, Uhagaze DS, Ding X, Dong Y. Determination of pKa values of alendronate sodium in aqueous solution by piecewise linear regression based on acid-base potentiometric titration. J Pharm Anal. 2016 Dec;6(6):404-409. doi: 10.1016/j.jpha.2016.07.001. Epub 2016 Jul 9. PubMed PMID: 29404010; PubMed Central PMCID: PMC5762946. 16: Nguyen TD, Pitchaimani A, Aryal S. Engineered Nanomedicine with Alendronic Acid Corona Improves Targeting to Osteosarcoma. Sci Rep. 2016 Nov 8;6:36707. doi: 10.1038/srep36707. PubMed PMID: 27824143; PubMed Central PMCID: PMC5099855. 17: Davis S, Martyn-St James M, Sanderson J, Stevens J, Goka E, Rawdin A, Sadler S, Wong R, Campbell F, Stevenson M, Strong M, Selby P, Gittoes N. A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures. Health Technol Assess. 2016 Oct;20(78):1-406. Review. Erratum in: Health Technol Assess. 2018 Mar;20(78):407-424. PubMed PMID: 27801641; PubMed Central PMCID: PMC5107884. 18: Laius O, Maasalu K, Kõks S, Märtson A. Use of drugs against osteoporosis in the Baltic countries during 2010-2014. Medicina (Kaunas). 2016;52(5):315-320. doi: 10.1016/j.medici.2016.10.001. Epub 2016 Oct 13. PubMed PMID: 27789081. 19: Belhassen M, Confavreux CB, Cortet B, Lamezec L, Ginoux M, Van Ganse E. Anti-osteoporotic treatments in France: initiation, persistence and switches over 6 years of follow-up. Osteoporos Int. 2017 Mar;28(3):853-862. doi: 10.1007/s00198-016-3789-y. Epub 2016 Oct 20. PubMed PMID: 27766368. 20: Saatchi K, Tod SE, Leung D, Nicholson KE, Andreu I, Buchwalder C, Schmitt V, Häfeli UO, Gray SL. Characterization of alendronic- and undecylenic acid coated magnetic nanoparticles for the targeted delivery of rosiglitazone to subcutaneous adipose tissue. Nanomedicine. 2017 Feb;13(2):559-568. doi: 10.1016/j.nano.2016.08.012. Epub 2016 Aug 21. PubMed PMID: 27558352.